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Vectors mediating strong, durable, and tissue- speciﬁc 
transgene expression are mandatory for safe and  effective 
gene therapy. In settings requiring systemic vector admin-
istration, the availability of suited vectors is extremely lim-
ited. Here, we present a strategy to select vectors with true 
speciﬁcity for a target tissue from random peptide libraries 
displayed on adeno-associated virus (AAV) by screening 
the library under circulation conditions in a murine model. 
Guiding the in vivo screening by next-generation sequenc-
ing, we were able to monitor the selection kinetics and to 
determine the right time point to discontinue the screen-
ing process. The establishment of different rating scores 
enabled us to identify the most speciﬁcally enriched AAV 
capsid candidates. As proof of concept, a capsid variant 
was selected that speciﬁcally and very efﬁciently delivers 
genes to the endothelium of the pulmonary vasculature 
after intravenous administration. This technical approach 
of selecting target-speciﬁc vectors in vivo is applicable to 
any given tissue of interest and therefore has broad impli-
cations in translational research and medicine.
Received 5 October 2015; accepted 16 March 2016; advance online  
publication 26 April 2016. doi:10.1038/mt.2016.62
INTRODUCTION
The lack of vectors mediating strong and durable gene expression 
specifically in a single tissue of interest after simple intravenous 
injection is a major obstacle on the way to success in gene therapy.
The vascular endothelium expresses tissue-specific receptors, 
which enables the specific homing of circulating ligands under 
normal and pathologic conditions. This vascular heterogeneity has 
been characterized extensively and ligands that home to defined 
tissues after intravenous injection have been isolated by screening 
phage display peptide libraries in vivo.1–6 Exploiting such tissue-
specific ligand-receptor pairs for the targeting of drugs or genes3–
5,7,8 holds major promise. Nevertheless, it has been difficult to use 
such ligands for tissue-specific gene transfer by viral vectors suit-
able to be used in clinical settings.
Adeno-associated virus (AAV)-based vectors are considered 
safe and effective, they have been used in many clinical trials9–11 
and one of them has been even approved as first commercial gene 
therapy drug in the European Union.12 The various AAV sero-
types vastly differ in their tropism13–17 but none is specific towards 
only one single tissue after systemic administration,17 the most 
favorable way of vector administration for the majority of gene 
therapy applications. Mixing capsid subunits of different AAV 
serotypes can redirect and improve transduction of target tissues 
to some extent.18–28 Due to the limited diversity of pre-existing 
capsid proteins, however, real vector specificity has rarely been 
achieved by this approach. Many of the targeting peptides iden-
tified by phage display or other ligands have been inserted into 
the structural context of the AAV capsid.5,6,29–34 While this can 
improve transduction properties in certain settings, such vectors 
lack true tissue specificity because the properties of incorporated 
peptides can change with their surrounding structural context. 
Random AAV display peptide libraries may circumvent this prob-
lem as they allow the selection of targeting ligands directly in the 
structural constraint of the AAV surface.35–37 Several vector cap-
sids that mediate improved transduction of their target cells have 
been selected from such libraries in vitro35–42 and in vivo.39,43–46 
However, none of these peptide library approaches have yet estab-
lished true vector specificity after systemic administration, except 
for tropism towards the heart44 the transduction of which may 
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be an indirect effect of manipulations of the AAV2 capsid region 
mediating primary receptor attachment.47 Overall, the number 
of approaches that have employed AAV library selection39,44,46 or 
directed evolution25–28 upon systemic administration in vivo is 
limited, which might explain that tissue-selectivity in vivo has 
rarely been achieved yet.
In this study, we demonstrate that real vector specificity and 
high transduction efficiency in vivo can indeed be obtained by 
screening AAV display peptide libraries in a murine model. We 
guided our selection by next-generation sequencing (NGS) analy-
sis of enriched clones that were recovered during several selec-
tion rounds in an in vivo screening protocol in mice. Choosing 
the therapeutically highly relevant pulmonary vasculature as tar-
get tissue, we were able to select an AAV capsid showing unprece-
dentedly efficient and tissue-specific transduction patterns, based 
on organ-specific vector homing to the endothelium after intra-
venous administration. This strategy does not only have practical 
implications for the field of pulmonary medicine as it may also be 
applicable to any other tissue of interest for in vivo gene delivery.
RESULTS
Screening the random AAV-display peptide library for 
lung-targeted capsids in vivo yields a distinct peptide 
sequence
To select specific tissue-targeted AAV2 capsids, an AAV2-displayed 
random heptamer peptide library was screened in vivo in mice, 
choosing the lung as the target of interest. Library particles were 
injected intravenously and given 2 days for homing and target 
cell infection under normal circulation conditions. The lung was 
removed and total DNA including the lung-homing library parti-
cles’ genomes was isolated. The random oligonucleotides contained 
in the enriched AAV particles were amplified by nested- polymerase 
chain reaction (PCR) and recloned into library plasmids for generat-
ing a secondary AAV peptide library for the next round of selection. 
In rounds 2–5, time to tissue harvest was extended to 6 days to better 
eliminate circulating unspecific particles. Recovered library genomes 
were analyzed by NGS after each round of selection (Figure 1). The 
complete NGS data have been deposited at the European Nucleotide 
Archive under Genbank accession no. PRJEB9646.
In the early phase of the selection, NGS revealed strong vari-
ability of the recovered library inserts, indicated by frequent 
changes of the most dominant peptides during the first four selec-
tion rounds. To better understand the kinetics of selection, we 
analyzed the change in relative frequency of the most dominant 
peptides during subsequent selection rounds. The median of the 
change in relative peptide frequency between subsequent selec-
tion rounds exceeded factor 6,000 among the 20 most dominant 
sequences (T20 Median). From round four–five, however, sta-
bilization occurred, resulting in a decline of the T20 Median to 
0.7. This was interpreted as an indicator for the beginning of the 
late selection phase in which well transducing capsid variants had 
been enriched sufficiently. Thus, the selection process was dis-
continued at this point and the recovered clones were analyzed 
regarding potential target transduction efficiency and specificity. 
To exclude irrelevant, less abundant sequences, only those were 
analyzed that individually accounted for >0.02% of all reads which 
combined made up >99% of all reads.
Our previous experience with in vivo screenings of AAV 
libraries as well as the NGS-based data presented here, indicate 
that even after five rounds of selection, a still very large diversity of 
recovered clones can make the identification of the most promis-
ing candidates very difficult. Therefore, we established three rat-
ing scores to allow such identification from the large total number 
of recovered candidates, based on relative frequency of a given 
clone in the target tissue and its specificity, i.e., its distribution in 
the target compared to control organs (Figure 2). At the time the 
selection was terminated, the relative frequency of the peptides 
might not have accurately reflected their transduction effica-
cies, as some less abundant sequences still increased in relative 
frequency. To evaluate this, we defined an enrichment score “E”, 
reflecting changes in relative abundance from before-last (Ry) to 
last (Rz) (i.e., fourth to fifth) selection round:
E = 
R
R
z
y
1
1
1
–
 +
To evaluate tissue specificity, we performed deep sequencing of 
clones from three off-target organs (heart, liver, and kidney) after 
five selection rounds with the lung as target organ and compared 
their relative abundances (Ry) with those found within the lung 
as primary target (Rz). Therefore, we determined three organ- 
dependent specificity scores Sheart, Sliver, and Skidney using the same 
term as for the enrichment score E (see above). S values range 
from 0 to 1, with 0 representing the lowest and 1 the highest speci-
ficity. A general specificity score, GS was determined by multiply-
ing the individual scores: GS = Sheart × Sliver × Skidney. This algorithm 
delineates target tissue specificity as it strongly “punishes” abun-
dance in even a single off-target organ. To determine the most 
promising peptide regarding specificity and efficacy, a combined 
score “C”, was determined by multiplying GS and E (Figure 2).
Analysis of the enrichment score E indicated that the sequence 
motif G-G/E-G/D-L-T/S-R-A was strongly enriched, as was pep-
tide ESGHGYF (Figure 2a). In GS- (Figure 2b) and C-score 
(Figure 2c), ESGHGYF dominated over all other sequences, 
suggesting it to be a highly specific and efficient lung targeting 
peptide. Therefore, the AAV capsids with ESGHGYF insert was 
chosen for further analyses.
AAV2 vectors displaying the ESGHGYF peptide 
mediate strong and speciﬁc gene expression in the 
lung
To analyze the in vivo tropism, targeting and control peptides were 
incorporated into the capsids of AAV vectors carrying a luciferase 
reporter gene. The peptide insertions appeared not to negatively 
influence capsid assembly or gene packaging as titers were com-
parable to unmodified capsid vectors. Vectors were injected intra-
venously into mice and bioluminescence was imaged in vivo after 
14  days (Figure 3a). Indeed, the top-scoring peptide ESGHGYF 
mediated strong and lung-specific transgene expression. A random 
control clone from the unselected library (CVGSPCG) mediated 
weak gene expression mainly in the heart, and wild-type AAV2 
mediated gene expression mainly in the liver. Both controls did not 
confer visible transgene expression in the lung. Almost no variability 
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between repetitive experiments was observed (see Supplementary 
Figure S1), indicating a high degree of reproducibility. Three-
dimensional reconstruction of bioluminescence images including 
virtual cross sections of a mouse injected with rAAV2-ESGHGYF 
vector confirmed lung specific expression (Figure 3b). In vivo 
data were also confirmed by imaging representative tissues ex vivo 
immediately after organ removal from ESGHGYF-injected animals 
(Figure 3c), whereas at the same rating scale, the weak lumines-
cence signal mediated by control vectors was barely detectable ex 
vivo in any of the organs (data not shown).
The ESGHGYF-mediated, lung-targeted luciferase transgene 
expression was analyzed over 244 days after injection and quan-
tified as emitted radiance from the lung as the defined region 
of interest (ROI) (Figure 3d). Throughout the whole period, 
transgene expression was stable at high levels and continued to 
be restricted to the lung. It peaked at day 14, and only showed a 
limited decrease until day 244 (Figure 3d; for original lumines-
cence images with exact delineation of ROIs see Supplementary 
Figure S2). Of note, the specific transduction of lung tissue, that 
was observed after intravenous injection of rAAV2-ESGHGYF, 
was also seen after intraperitoneal vector administration (see 
Supplementary Figure S3), attesting to the specificity of the 
selected vector.
For additional quantitative accuracy, luciferase activity in tis-
sue lysates of representative organs was determined 14 days after 
vector injection (Figure 4a). Here, wild-type AAV2 mediated weak 
gene expression in brain, liver and kidney and even less in all other 
tested organs. The random control peptide CVGSPCG mediated 
moderate gene expression in the heart (a common observation for 
capsids modified in the heparan sulfate-binding region47). In con-
trast, vectors displaying the peptide ESGHGYF mediated strong 
and specific gene expression in the lung (Figure 4a), confirming 
the intravital imaging results. In liver and heart—the most fre-
quently transduced organs by AAV2—lung-targeted ESGHGYF 
vectors only mediated gene expression at background level. In 
the lung, in contrast, ESGHGYF conferred transgene expression 
>200× higher than wild-type AAV2 or CVGSPCG control vectors 
(Figure 4b).
The impact of individual amino acids within the ESGHGYF 
peptide on the viral capsid was analyzed by alanine scanning 
Figure 1  Next-generation sequencing (NGS)-guided in vivo selection of a random X7-peptide adeno-associated virus (AAV) display library for 
identiﬁcation of efﬁcient and speciﬁc capsid targeting peptides. A random AAV display peptide library was injected intravenously in mice. Two 
(ﬁrst selection round) or 6 (selection rounds 2–5) days after library administration, total DNA was isolated from the tissue of interest. The viral DNA 
containing the random library oligonucleotides of particles enriched in the target tissue was ampliﬁed by nested polymerase chain reaction (PCR) 
and cloned into library plasmid backbones to generate a secondary AAV display peptide library by transfection of AAV producer cells. The secondary 
library was used for a subsequent round of selection. NGS was used to analyze the selected oligonucleotide sequences after PCR-ampliﬁcation from 
total DNA, isolated from murine lungs. Median of the changes in relative abundance of the 20 most frequent sequences (T20 Median) between 
the individual rounds was determined. As this median value sharply declined between rounds four and ﬁve, the selection process was stopped, and 
PCR-ampliﬁed virus DNA from the target and off-target organs was analyzed. Speciﬁcity and efﬁcacy of dominant capsid variants was scored and 
AAV2-ESGHGYF was selected for further validation.
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mutagenesis. No abrogation of lung tropism was observed when 
replacing the first two amino acid positions of the inserted pep-
tide by alanine, whereas replacements at all other positions either 
resulted in subtotal transduction deficiency (positions 3–4) 
or in retargeting toward heart and skeletal muscles (positions 
5–7). These tissues were also transduced by capsids harboring a 
scrambled version (FHEYGSG) of the lung-homing peptide (see 
Supplementary Figure S4). Transduction of lung tissue by AAV2-
ESGHGYF vector could not be blocked by soluble ESGHGYF 
peptide (see Supplementary Figure S5 and Supplementary 
Materials and Methods), indicating that the lung tropism is caused 
by the structural changes of the viral capsid (that are conferred by 
the ESGHGYF peptide) rather than the isolated peptide itself.
ESGHGYF-mediated targeting is based on lung-
speciﬁc homing of circulating vectors
To investigate if the lung-specific transgene expression of intra-
venously administered ESGHGYF vectors is based on specific 
Figure 2 Scoring of dominant capsid variants for speciﬁcity and efﬁcacy. After ﬁve selection rounds, the targeting peptides accounting for >99% 
of all reads from the lung in the next-generation sequencing analysis were scored. Peptides appear in order of their relative abundance in the lung 
from left to right, ranging from PRSADLA (32.74%) to GGDLSRA (0.02%). Three of the displayed peptides deviate in length. (a) The enrichment score 
E describes for the target tissue the change in relative abundance from selections round four to ﬁve within a range from 0 to 1. Peptides with the same 
relative abundance in both rounds yield a value of 0.5 (dashed line), highly enriched sequences yield a value close to 1. (b) The general speciﬁcity 
score GS is a combination of the organ-speciﬁc S scores and describes the target speciﬁcity of a peptide. Peptides with the same relative abundance 
in lung and all three control organs score at 0.125 (dashed line). With increasing speciﬁcity, the score increases toward 1. (c) The combined score C is 
generated by multiplying E and GS scores and describes the peptide performance regarding speciﬁcity and efﬁcacy with an ideal value of 1. A peptide 
that doubles its relative abundance from round four to ﬁve and shows only half of the relative abundance observed in the lung in all three off-target 
organs scores at 0.198 (dashed line). ESGHGYF was the only analyzed peptide exceeding these criteria.
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homing, we analyzed the vector distribution as early as 2 min-
utes after injection (Figure 5a). Quantification of vector genomes 
by real-time PCR revealed lung-specific homing of AAV2-
ESGHGYF with vector copy numbers being 5–30 times higher in 
the lung than in any other organ, whereas wild-type AAV2 was 
recovered mainly from heart and liver. At this time point a con-
siderable amount (~1/3) of the injected wild-type and ESGHGYF 
particles were still in the circulation and could be recovered from 
left ventricular blood (Figure 5a). The relative enrichment of 
ESGHGYF particles in the lung compared to off-target organs 
Figure 3 Luminescence imaging of mice after intravenous injection of AAV-vectors carrying a luciferase reporter gene. (a) Images were taken 14 days 
after i.v. administration of 5 × 1010 gp/mouse of vectors displaying the peptide ESGHGYF selected for lung tropism, the random control peptide CVGSPCG, or 
wild-type AAV2 capsids, respectively. Mice were imaged from the back (left panel), from the side (intermediate panel) and from the front (right panel). Images 
show representative examples of >3 animals per group. (b) Sagittal, coronal, and transaxial sections (left panel) and three-dimensional reconstruction (right 
panel) of the luminescence images of a mouse injected with AAV2-ESGHGYF vector (as in a), obtained by measuring different wavelengths of the emitted 
light, conﬁrming the lung as source of luminescence. (c) Single organ of an ESGHGYF-injected mouse (as in a), measured ex vivo immediately after tissue 
explantation. (d) ESGHGYF-displaying vector was administered and long-term transgene expression was analyzed by bioluminescence imaging at 14-time 
points during a 244 days period (n = 2 animals). Upper panel: Imaged mice, rainbow scale as in a. lower panel: Values of luminescence/ region of interest.
AAV2-ESGHGYF
1.0
0.8
0.6
×105
0.4
0.2
Radiance
(p/sec/cm2/sr)
1.0
0.8
0.6
×105
0.4
0.2
Radiance
(p/sec/cm2/sr)
1.0 × 107
1.0 × 106
Lu
m
in
es
ce
nc
e/
 R
O
I
(p/
se
c/c
m2
/s
r)
1.0 × 105
0 28 56 84 112 140
Days postinjection
168 196 224 252
7 14 21 28 35 42 56
70 84 98 126 158 187 244
Luminescence
×105
0.5
1.0
1.5
2.0
Radiance
(p/sec/cm2/sr)
AAV2-CVGSPCG
AAV2-WT
a b
c
d
1054 www.moleculartherapy.org vol. 24 no. 6 jun. 2016
© The American Society of Gene & Cell Therapy
In vivo Screening of AAV Display Peptide Libraries
further increased and after 4 hours 6–100 times higher copy num-
bers were detected in the lung than in the control organs (see 
Supplementary Figure S6).
To analyze the correlation between vector homing and trans-
gene expression, vector distribution was also measured 14 days after 
injection, the point at which transgene expression was analyzed in 
parallel experiments (see above). Genomes delivered by wild-type 
AAV2 could be recovered mainly from liver, kidney, and spleen. 
The spleen also contained most genomes of vectors displaying the 
random control peptide. Overall, the amount of vector genomes 
in the spleen was approximately equal with all tested capsid vari-
ants, suggesting nonspecific particle uptake in the reticular endo-
thelial system, which is independent of transgene delivery and 
expression. In contrast, distribution of genomes delivered by the 
lung-targeted ESGHGYF-vectors strongly resembled the transgene 
expression data with highly specific enrichment in the lung. The 
amount of ESGHGYF-vector genomes in the lung was up to 250-
fold higher than in the other organs and up to 470-fold higher than 
in lungs injected with wild-type or control capsid vectors (Figure 
5b). The same vector genome distribution ratio between the organs 
was found 28 days after vector administration (data not shown). 
Direct comparison of the vector genome quantities between the 
three capsid variants is shown in Figure 5c for the three tissues in 
which relevant quantities of vector DNA could be detected. Taken 
together, these data suggest that ESGHGYF-mediated lung-specific 
transgene expression is brought about by tissue-specific homing of 
circulating vector particles. Albeit proving a strong influence on the 
viral tropism, the insertion of the ESGHGYF peptide did not seem 
to alter either reactivity with preexisting serum antibodies or the 
antibody response compared to wild-type AAV2. We found similar 
amounts of neutralizing antibodies against wild-type and the modi-
fied capsid in pooled human intravenous immunoglobulin and the 
sera of individual human subjects (see Supplementary Figure S7 
and Supplementary Materials and Methods). Further, both capsid 
variants (wild-type or ESGHGYF) induced a cross-reactive neutral-
izing antibody response in mice (see Supplementary Figure S8 and 
Supplementary Materials and Methods).
AAV2-ESGHGYF delivers genes selectively to 
pulmonary endothelial cells
To identify the primary target of AAV2-ESGHGYF, we visualized 
transgene expression at the cellular level in the lung and a control 
organ 14 days after intravenous administration of AAV vectors 
(rAAV2) carrying the eGFP gene. In lungs of mice injected with 
rAAV2-ESGHGYF, immunohistochemistry revealed intense staining 
in endothelial cells throughout the entire pulmonary microvascula-
ture and, slightly less intense, in larger pulmonary vessels (Figure 6a). 
In contrast, pulmonary tissue of mice injected with wild-type capsid 
rAAV2 showed no staining (Figure 6a). The liver (a tissue known 
to exhibit strong transgene expression after wild-type rAAV2 vector 
injection) was analyzed as control. Here, staining of hepatocytes was 
observed after wild-type rAAV2 but not after rAAV2-ESGHGYF 
Figure 4 Determination of luciferase activity from tissue lysates. Luciferase transgene expression analysis in tissue lysates 14 days after vector 
administration. Data are shown as bars (mean) with plotted individual data points (n = 3 animals per group). (a) Organ distribution of luciferase 
transgene expression mediated by the three vectors as detailed in Figure 3a. (b) Direct comparison of transgene expression mediated by vectors 
carrying wild-type AAV2 capsids (AAV2-WT), CVGSPCG-displaying control capsids or ESGHGYF-displaying lung-targeted capsids in three organs in 
which transgene expression could be detected by bioluminescence imaging (heart, liver, and lung).
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administration (Figure 6b). The endothelial nature of the vector-
transduced pulmonary cells was confirmed by CD31 staining, which 
exactly reproduced the eGFP staining pattern in serial sections of 
lungs of rAAV2-ESGHGYF injected mice (Figure 6c).
DISCUSSION
Targeting vectors specifically to a tissue of interest after systemic 
administration has been an urgent but largely unmet need ever 
since the earliest days of gene therapy. Many targeting strategies 
have been developed but so far none of them could solve this 
problem completely.
To address this, we and others have introduced a vector evo-
lution system enabling the selection of targeting ligands within 
the structural constraint of the viral capsid of AAV.35,36 While 
theoretically this system promises almost unlimited versatility in 
the development of specific vectors for any conceivable cell type 
of interest, so far its major use has been to select targeted vec-
tors in vitro.35–41 Screening such libraries in vivo, however, mostly 
yielded vectors either with moderate transduction efficiency in 
the target tissue or low tissue specificity39,46 after systemic admin-
istration. Here, we present an improved system for in vivo selec-
tion of AAV display libraries and therefore introduce for the first 
Figure 5 Biodistribution of recombinant adeno-associated virus (AAV) vectors. Amounts of vectors were determined by quantitative real-time 
PCR of vector genomes. All experiments were performed after i.v. administration of 5 × 1010 gp/mouse. Data are shown as bars (mean) with plotted 
individual data points (n = 3–4 animals per group). (a) Distribution of wild-type AAV2 (left) and AAV2-ESGHGYF (middle) in seven analyzed organs, 2 
minutes after vector administration, reﬂecting tissue homing of injected particles. Amount of circulating particles recovered from left ventricular blood 
(right). (b) Distribution of genomes delivered by AAV2-ESGHGYF or control vectors (wild-type AAV2 and AAV2-CVGSPCG), respectively, 14 days after 
vector administration. (c) Separate depiction of vector genome quantities in the three organs containing the highest amount of vector genomes 
(liver, spleen, and lung) comparing the three capsid variants used for gene delivery.
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time a tailored, truly tissue-specific, and very effective vector 
system.
Two determinants decide on the success of screening ran-
dom AAV libraries in vivo: (i) the biological selection process 
itself with parameters such as amount of administered particles, 
circulation time, way of amplifying enriched clones from one 
selection round to the next, etc. and (ii) detection of the relevant 
clones within the large amount of recovered particles because 
the most abundant clones may not have the strongest trans-
duction efficiencies and not the most specific homing proper-
ties to the tissue of interest. Besides optimizing the first point, 
we have addressed the second point by large-scale analysis of 
recovered clones and establishing a biomathematical algorithm 
that allows (i) to identify the suitable time point to discontinue 
the selection procedure and (ii) to select the capsid variant with 
the highest potential regarding transduction efficacy and target 
specificity for further evaluation. As early as in the first round 
of the selection, our NGS analyses revealed dominance of cer-
tain capsid variants. However, such dominance fluctuated from 
one round to the next, with different clones being prominent 
in each round. This variability could be due to the initially low 
copy numbers of each clone in the library. Therefore, some clones 
may not be evenly distributed despite their unselective tropism. 
Random recovery of such clones from the target organ and sub-
sequent highly effective amplification can suggest dominance 
despite nonspecificity. Over several selection rounds, this effect 
Figure 6 AAV2-ESGHGYF-mediated speciﬁc gene delivery to pulmonary vasculature endothelial cells. Parafﬁn-embedded tissue sections of 
mouse lungs and control organs were stained by immunohistochemistry 14 days after i.v. vector administration of 1 × 1011 gp/mouse (AAV2-ESGHGYF 
or wild-type AAV2 as control). Each panel a and b displays a representative area of the tissue of interest, shown in different magniﬁcations. Size of 
scale bars: 100 μm at 20× magniﬁcation; 50 μm at 40× magniﬁcation; and 20 μm at 100× magniﬁcation. (a) Representative area of the lung stained 
with an antibody against the transgene product GFP. Red arrow: Example of endothelial cells of larger pulmonary vessel; Blue arrow: Example of 
endothelial cells of pulmonary microvasculature. (b) Representative area of the liver stained with an antibody against GFP. Black arrows: examples of 
transduced hepatocytes (c) serial sections of a representative area of the lung of mice injected with rAAV2-ESGHGYF, stained with antibodies against 
the endothelial marker CD31 and against the transgene product GFP.
20×
AAV2-ESGHGYF AAV2-ESGHGYF
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100×40× 20× 100×40×
100×40×
αCD31
αGFP
a
c
b
Molecular Therapy vol. 24 no. 6 jun. 2016 1057
© The American Society of Gene & Cell Therapy
In vivo Screening of AAV Display Peptide Libraries
diminishes as truly specific clones become steadily enriched in 
the target organ while others decrease in relative frequency due 
to nonspecific homing, resulting in dominant recovery, amplifi-
cation, and visibility of capsid variants with superior target trans-
duction. Analogous to phage display library screenings,48,49 the 
selection process was discontinued upon such decrease in vari-
ability. Nevertheless, the diversity of recovered clones was large 
at this point. NGS has repeatedly been used to identify targeting 
clones from phage and antibody display libraries, setting focus 
on the reduction of selection rounds more than on specificity.50–52 
Here, we expanded the scoring analysis to the distribution of 
peptide variants in three off-target tissues, which was the key to 
identifying the enriched clone with target transduction efficiency 
and specificity. During preparation of the NGS probes, the crude 
tissue DNA was subjected to different PCR amplification steps to 
enrich the AAV library DNA and to add the necessary sequenc-
ing barcodes. Thus, the number of NGS reads from a given probe 
does not directly reflect the absolute number of library genomes 
in the respective organ. Our analysis was solely focused on the 
relative abundance of individual clones in each organ. The valid-
ity of our determined scores is confirmed by comparing them 
with functional data available for some of the recovered peptides. 
The most frequent peptides were PRSADLA and PRSTSDP, but 
both possess a low GS score. In congruence with this, we pre-
viously observed that both peptides mediate lung transduction 
but also strongly transduce liver, heart, and kidney.39 Similarly, 
EYRDSSG and NDVRAVS, both with a low GS score, have been 
shown to confer high transduction efficiency but only low organ 
specificity.35,39 The peptide ESGHGYF had by far the highest GS 
and C scores, and indeed showed uniquely strong transduction 
efficiency and specificity for the lung as the target tissue of this 
library selection. Of note, ESGHGYF represented only 6% of all 
reads in the lung after five rounds of selection and very likely 
would have been overlooked in a conventional analysis solely 
focusing on clone dominance.
The specificity of transgene expression in the pulmonary 
endothelium correlated with vector distribution, which indicates 
true specificity in gene delivery as opposed to a mere optimization 
of postentry vector processing. This unprecedented strength and 
specificity of transgene expression after systemic administration 
is composed of both, targeting to the lung and detargeting espe-
cially from the liver. Frequently, AAV2 capsid changes sterically 
close to the 588 site not only result in liver de-targeting but also 
augment gene expression in the heart.39,44,47 This was reconfirmed 
in our experiments with the control vectors displaying peptides 
CVGSPCG and FHEYGSG and by alanine scanning. In view of 
that it is remarkable, that the tropism of the ESGHGYF clone 
selected by using the technology described here did not show this 
pattern and was restricted to the lung.
The amino acid sequence of the ESGHGYF peptide does not 
show any striking similarities with one the different lung-homing 
peptides that have previously been identified by the phage display 
technique. The GFE-1 peptide (CGFECVRQCPER) was identi-
fied in vivo in murine lungs2 and has later been shown to bind 
the cell surface protein membrane dipeptidase,53 whereas the 
CGSPGWVRC peptide was identified in vitro on immortalized 
murine lung endothelial cells.54 Recently a tissue-penetrating 
homing peptide (CARSKNKDC) has been shown to confer 
selective homing to hypertensive pulmonary arteries but not 
to normal pulmonary vessels55 in a heparin sulfate-dependent 
manner.56 However, none of these peptides shares a common 
sequence motif with the ESGHGYF peptide. This is not surpris-
ing and can most likely be explained by the fundamental differ-
ences of the library systems that have been used to identify these 
peptides. The phage display technique allows the selection of well 
accessible peptides that are terminally fused to the phage’s coat 
protein without being forced into major structural constraints. 
In an AAV display library, on the other hand, the peptides are 
embedded within a structurally very important area of the viral 
capsid, in which they may be forced into strong physicochemical 
constraints. Thus, in an AAV display library it is not necessarily 
the isolated peptide which is being selected for, more likely it is 
the modified viral capsid being structurally altered by insertion 
of this peptide. This also explains why the soluble ESGHGYF 
peptide did not show any effect in the competition assay with the 
AAV2-ESGHGYF vector.
Although the receptor targeted by the AAV2-ESGHGYF 
capsid has not been identified yet, the carbohydrates on the 
endothelial cell surface presumably are essential for specific tar-
geting, since glycans are used as primary attachment receptors 
by all AAV serotypes analyzed so far.57 Our data indicate a spe-
cific receptor-mediated homing of AAV2-ESGHYGF to pulmo-
nary endothelial cells rather than a global endothelial tropism 
with enrichment in the lung merely due to a first pass effect: 
(i)   different injection routes (intravenous and intraperitoneal) 
led to specific enrichment in the lung and detargeting from the 
liver, although the majority of vector administered into the peri-
toneal cavity is supposed to enter the circulation via the portal 
vein, passing the hepatic sinusoids as first large vascular bed58; 
(ii) 2 minutes after intravenous injection (after ~10–50 circula-
tion rounds59,60) as much as one-third of the injected vector cop-
ies could still be detected in the blood collected from the left 
ventricle, and—albeit being enriched in the lung—considerable 
particle numbers, likely still being in circulation, could be recov-
ered from well perfused nontarget organs like brain, heart, and 
kidney. This would not have been the case if the lung-homing was 
solely explained by a first pass effect.
Although the insertion of the ESGHGYF peptide into the 
AAV2 capsid does not seem to have an positive influence on the 
antibody reactivity, the AAV2-ESGHGYF vector might very well 
be a promising candidate for gene therapy, as there are different 
potential options to circumvent unwanted immune responses in a 
clinical setting such as plasmapheresis61 or blocking of antibodies 
by applying an excess of empty particles.62 Taken together, this is 
the first report on the systematic selection of a gene therapy vec-
tor mediating strong and durable expression specifically in a target 
tissue other than the heart under circulation conditions in vivo. 
Thus, choosing the lung as therapeutically highly relevant target, 
vectors such as the one presented here might be used in gene ther-
apy for disorders like pulmonary hypertension. Our NGS-guided 
approach of in vivo selection allows unprecedented exploitation of 
the high potential of random AAV display peptide libraries and 
could be used to obtain specific vectors for virtually any given tar-
get organ.
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MATERIALS AND METHODS
Preparation of the random AAV display peptide library. A random X7 
AAV2 display peptide library with a theoretical diversity of 1 × 108 unique 
clones was produced using a two-step protocol as previously described.35,37 
In short, the degenerate oligonucleotide encoding seven random amino 
acids (encoded by NNK) at nucleotide position 3967 in the AAV genome 
(amino acid position R588; VP1 numbering) was synthesized (Metabion, 
Martinsried, Germany) as follows: 5′-CAGTCGGCCAGAGAGGC(NNK)7 
GCCCAGGCGGCTGACGAG-3′. The second strand was synthesized 
by using sequenase (Amersham, Freiburg, Germany) and the primer 
5′-CTCGTCAGCCGCCTGG-3′. The double-stranded insert was cleaved 
with BglI, purified with the QIAquick Nucleotide Removal Kit (Qiagen, 
Hilden, Germany) and ligated into the SfiI-digested pMT187-0–3 library 
plasmid.35 The diversity of the plasmid library was determined by the 
number of clones growing from a representative aliquot of transformed 
electro competent DH5α bacteria on agar containing 150 mg/ml ampicil-
lin. Library plasmids were harvested and purified using Qiagen’s Plasmid 
Preparation Kit. The AAV library genomes were packaged into chimeric 
wild-type and library AAV capsids (AAV transfer shuttles) by transfect-
ing 2 × 108 293T-cells in ten 14.5-cm cell culture dishes at a 1:1:2 ratio of 
the plasmid pVP3cm (containing the wild-type cap gene with modified 
codon usage, without inverted terminal repeats),37 the library plasmids 
and the pXX6 helper plasmid.63 The resulting AAV library transfer shut-
tles were used to infect 2 × 108 293T-cells in ten 15-cm cell culture dishes 
at a multiplicity of infection (MOI) of 0.5 replicative units per cell. Cells 
were superinfected with Ad5 at an MOI of five plaque-forming units 
(pfu) per cell. The final random peptide AAV display library was har-
vested from the supernatant after 48 hours. The supernatant was con-
centrated using VivaSpin columns (Viva Science, Hannover, Germany), 
purified by iodixanol density gradient ultracentrifugation as previously 
described64 and titered by quantitative real-time PCR (qPCR) using the 
cap-specific primers 5′-GCAGTATGGTTCTGTATCTACCAACC-3′ and 
5′-GCCTGGAAGAACGCCTTGTGTG-3′ with the LightCycler system 
(Roche Diagnostics, Mannheim, Germany).
In vivo screening of the random AAV display peptide library. 1 × 1011 
genomic library particles were injected into the tail veins of healthy FVB/N 
mice (see below). After 48 hours, mice were sacrificed and organs of inter-
est were removed. Total tissue DNA was extracted using the DNeasy tis-
sue kit (Qiagen). The random oligonucleotides contained in AAV library 
particles which were enriched in the tissue of interest were amplified by 
nested PCR using the primers 5′-ATGGCAAGCCACAAGGACGATG-3′ 
and 5′-CGTGGAGTACTGTGTGATGAAG-3′ for the first PCR and 
5′-GGTTCTCATCTTTGGGAAGCAAG-3′ as well as 5′-TGATGAGAA 
TCTGTGGAGGAG-3′ for the second PCR. The PCR-amplified oligo-
nucleotides were used to produce secondary libraries for four further 
rounds of selection (mice were sacrificed 6 days after library injection in 
round 2–5). Secondary libraries were produced like the primary library (as 
described earlier) but without the extra step of producing transfer shut-
tles. The secondary plasmid library was directly used to transfect 2 × 108 
293T-cells in 15-cm cell culture dishes at a ratio of 25 library plasmids per 
cell, using Polyfect transfection reagent (Qiagen).
NGS of AAV peptide libraries. Amplicon libraries for illumina HiSeq2500 
NGS were generated from corresponding peptide library DNA in two sub-
sequent PCR reactions. In the first PCR, a forward primer with an Index 
sequence (ATCGATCG, TCGATCGA, CGATCGAT or GATCGATC; e.g., 
5′-ACACTCTTTCCCTACACGACGCTCTTCCGATCTATCGATCGCT 
GTATCTACCAACCTCCAGAGAGG-3′) was used in combination with 
reverse primer 5′-CAAGCAGAAGACGGCATACGAGATCTCTTCCG 
ATCTCTGCCAGACCATGCCTGGAAGAACG-3′ to allow identification 
of individual samples. In the second PCR, the 5′ end of the amplicon was 
extended by forward primer 5′-AATGATACGGCGACCACCGAGATCT 
ACACTCTTTCCCTACACGACGCTCTTCCGATCT-3′ while the same 
reverse primer was used. For single read HiSeq2500 illumina sequencing 
100 μl of a 2 nmol/l DNA solution were used (2 × 10−13 mol). Data analysis 
was performed by a custom script (see Supplementary Note 1).
Vector production and quantiﬁcation. Recombinant AAV vectors were 
produced by triple transfection of HEK293T-cells. Cells were grown at 37 °C, 
5% CO2 in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, 
CA), supplemented with 1% penicillin/streptomycin (Invitrogen) and 
10% fetal calf serum (Biochrom, Berlin, Germany). Plasmid DNA (see 
below) was transfected into 293T-cells with Polyfect transfection reagent 
(Qiagen). Four days after transfection, cells were harvested, lysed, and vec-
tors were purified by iodixanol density-gradient ultracentrifugation as pre-
viously described.64 For transfections, we used pXX6 as adenoviral helper 
plasmid,63 the luciferase gene pUF2-CMV-luc,37 or the GFP gene pTR-
CMV-GFP65 and a plasmid encoding the AAV capsid of interest. Plasmids 
encoding the AAV capsid mutants which had previously been selected 
from the AAV library and wild-type controls were modified pXX2-187 in 
ref. 38 and pXX2 in ref. 63, respectively. The oligonucleotide inserts encod-
ing the modified peptides for the alanine scan were synthesized (Metabion) 
and further processed as the library inserts (described earlier).
For quantification of vector stocks, genomic titers were determined 
by qPCR using the CMV-specific primers 5′-GGCGGAGTTGTT 
ACGACAT-3′ and 5′-GGGACTTTCCCTACTTGGCA-3′ using the 
LightCycler system (Roche), as previously described.66
Animals and vector administration. Initial in vivo selection with the 
random AAV2-peptide library, analysis of AAV luciferase expression vec-
tors, and neutralizing antibody assay were performed in 8–12 weeks old 
FVB/N mice. The peptide competition experiment and GFP reporter gene 
experiments for immunohistochemistry were performed in 8–12 weeks 
old SCID mice. All experiments involving animals were conducted in 
accordance with the German Animal Protection Code. The protocol was 
approved by the responsible ethics review board and the local authorities. 
All experiments were performed under anesthesia with 2% isoflurane and 
oxygen. AAV vectors were injected into the tail vein or the peritoneal cav-
ity at a total volume of 200 μl.
Assessment of luciferase reporter gene expression in vivo. AAV vec-
tors were administered intravenously or intraperitoneally at a dose of 
5 × 1010 vector genomes (vg) per mouse (n = 3 animals per injected AAV 
clone). At day 14, animals were anesthetized with isoflurane. Luciferase 
expression was analyzed using the Xenogen IVIS200 imaging system 
(Caliper Lifesciences, Hopkinton, MA) with the software Living Image 
4.0 (Caliper) after intraperitoneal injection of 200 μl luciferin substrate 
(150 mg/kg, Xenogen) per mouse. Representative in vivo bioluminescence 
transgene expression images from different positions (ventral, dorsal, and 
lateral) were taken when luminescence in relative light units (photons/
second/cm2) reached the highest intensity. Subsequently, animals were 
sacrificed, organs of interest were quickly removed and transgene expres-
sion images of single organs were taken immediately. Then, organs were 
snap frozen in liquid nitrogen and stored at −80 °C. Three-dimensional 
reconstructions of in vivo luminescence images were obtained by using 
the DLIT option of the software Living Image 4.0 (Caliper) and measur-
ing the emitted light in five different wavelengths from 560 to 640 nm, for 
3 minutes each.
To quantify luciferase expression, organs were homogenized in 
reporter lysis buffer (Promega, Madison, WI) using a Precelly’s 24 tissue 
homogenizer (Peqlab, Erlangen, Germany) according to the manufacturer’s 
instructions. Determination of luciferase reporter gene activity was 
performed in a luminometer (Mithras LB 940, Berthold Technologies, 
Bad Wildbad, Germany) over a 10-second interval after addition of 100 μl 
luciferase assay reagent (Promega) with 2 seconds delay between each 
measurement. Values were normalized to total protein levels in each sample 
with the Roti Nanoquant Protein Assay (Roth, Karlsruhe, Germany).
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Analysis of vector distribution. For quantification of vector genome copy 
number in various organs, total tissue DNA from each organ was extracted 
using a tissue homogenizer (Precelly’s 24 tissue homogenizer, Peqlab) and 
the DNeasy tissue kit (Qiagen) according to the manufacturer’s instruc-
tions at different time points after administration of 5 × 1010 vg per mouse. 
DNA was quantified using a spectral photometer Nanodrop ND-2000C 
(Peqlab, Erlangen, Germany). Analysis of AAV vector DNA in tissues was 
performed by qPCR using CMV-specific primers as previously described,66 
and normalized to 100 ng total DNA. For quantification of vector genome 
copy numbers in the circulation, blood was collected by left ventricular 
puncture and incubated for 10 minutes at room temperature. After centrif-
ugation for 2 minutes at 10,000 ×g the serum was directly used as template 
for qPCR. PCR efficiency was controlled by a spiked-in plasmid. Total copy 
numbers in the blood were calculated, assuming a blood volume of 100 ml/
kg body weight.67
Immunohistochemistry and histology. Lungs were fixed ex situ with 4% 
(w/v) paraformaldehyde via the trachea under a hydrostatic pressure of a 
20 cm water column for 20 minutes, followed by 24 hours immersion in the 
same fixative. Lung tissues were embedded in paraffin. Two-micrometer 
sections were dewaxed, rehydrated, and used for immunohistochemistry. 
Immunohistochemistry was performed with polyclonal antibodies against 
GFP (A-11122; Invitrogen) or CD31 (ab28364; Abcam, Cambridge, MA). 
Endogenous peroxidase activity was inactivated with 1% H2O2 in metha-
nol for 30 minutes. Prior to CD31 staining, sections were heated to 100 °C 
in citrate buffer, pH 6 for 20 minutes for antigen retrieval. After washing 
in phosphate-buffered saline, the sections were incubated for 30 minutes 
with phosphate-buffered saline, 10% goat serum (Vector Lab, Burlingame, 
CA), 2% powdered milk (Roth). Primary antibodies were allowed to bind 
for 1 hour at 37 °C. After washing in phosphate-buffered saline, the sec-
tions were incubated for 30 minutes with a secondary biotinylated goat 
antirabbit antibody (Vector Lab). Bound antibodies were visualized using 
the VECTASTAIN Elite ABC Kit (Vector Lab) and 3,3′-diaminobenzidine 
(Sigma-Aldrich, St. Louis, MO). Selected sections were counterstained with 
hemalum.
Photomicrographs were recorded by a digital camera (DP-25, 
Olympus, Tokyo, Japan) attached to a microscope (BX-51, Olympus) at 
10- to 100-fold magnification using the software cell^A (Olympus).
SUPPLEMENTARY MATERIAL
Figure S1. In vivo imaging of luminescence mediated by recombi-
nant AAV2 vectors.
Figure S2. Longterm transgene expression mediated by 
rAAV2-ESGHGYF.
Figure S3. In vivo imaging of luminescence mediated by rAAV2-
ESGHGYF after intraperitoneal injection.
Figure S4. Functional consequences of alanine scan or sequence 
scrambling of the peptide ESGHGYF.
Figure S5. Competition assay with soluble ESGHGYF peptide.
Figure S6. Biodistribution of AAV2-ESGHGYF, four hours after 
administration.
Figure S7. Prevalence of neutralizing antibodies against AAV2-WT 
and –ESGHGYF.
Figure S8. Neutralizing antibody response after injection of mice 
with AAV2-WT and –ESGHGYF.
Note S1. Bioinformatical data processing.
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